Description
XYREM ORAL MEDICATION
First action · last action
2015-10-01 · 2017-01-27
Transactions
3
First transaction's obligation
$263,542
Base + all options value (sum of deltas)
$232,168
Extent competed
FULL AND OPEN COMPETITION
Other than full & open authority
—
Set-aside
NO SET ASIDE USED.
Offers received
1
SDVOSB flag on record
No
Parent IDV
V797P5131B
NAICS
325412 · PHARMACEUTICAL PREPARATION MANUFACTURING
Modification chain · 3 transactions
Each row is one published transaction. This action is the obligation recorded on that transaction — a change amount, as USAspending publishes it. Running total is computed by Glassbox VA as the cumulative sum of those amounts up to and including the row, so the last running total equals the award's net obligations shown above. The cumulative-total columns in the source files are not used: they are not frozen per modification.
- Base2015-10-01+$263,542= $263,542
- Mod P000012016-07-08-$19,000= $244,542
- Mod P000022017-01-27-$12,374= $232,168
| Transaction | Action date | This action (delta) | Running total | Description on this transaction |
|---|---|---|---|---|
| Base | 2015-10-01 | +$263,542 | $263,542 | XYREM ORAL MEDICATION |
| Mod P00001· CHANGE ORDER | 2016-07-08 | −$19,000 | $244,542 | XYREM ORAL MEDICATION |
| Mod P00002· FUNDING ONLY ACTION | 2017-01-27 | −$12,374 | $232,168 | XYREM ORAL MEDICATION |
Related awards · 11
Awards are related by an explicit link in the data, stated for each group below — never by text similarity. Values are net obligations.
Other VA awards to the same recipient (UEI H9AXCNRA5NE6)
| Award | Office · PSC / listing | Net obligations | FY |
|---|---|---|---|
| 36C24526N0282 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $14,672 | FY2026 |
| 36C26026F0146 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $397,859 | FY2026 |
| 36C24526N0198 | 245-NETWORK CONTRACT OFFICE 5 (36C245) · 6505 · DRUGS AND BIOLOGICALS | $14,243 | FY2026 |
| 36C26026F0012 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $133,028 | FY2026 |
| 36C26026F0013 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $231,127 | FY2026 |
| 36C26026F0027 | 260-NETWORK CONTRACT OFFICE 20 (36C260) · 6505 · DRUGS AND BIOLOGICALS | $0 | FY2026 |
Other recipients under 6505 from 241-NETWORK CONTRACT OFFICE 01 (36C241) (most recent first)
| Award | Recipient | Office | Net obligations | FY |
|---|---|---|---|---|
| 36C24126P0328 | CARDINAL HEALTH 414, LLC | 241-NETWORK CONTRACT OFFICE 01 (36C241) | $999,797 | FY2026 |
| 36C24126F0121 | MCKESSON CORPORATION | 241-NETWORK CONTRACT OFFICE 01 (36C241) | $16,333 | FY2026 |
| 36C24126F0112 | VANTIVE US HEALTHCARE LLC | 241-NETWORK CONTRACT OFFICE 01 (36C241) | $545,567 | FY2026 |
| 36C24126N0603 | AMERICAN NATIONAL RED CROSS, THE | 241-NETWORK CONTRACT OFFICE 01 (36C241) | $1,998,719 | FY2026 |
| 36C24126F0109 | BOSTON SCIENTIFIC CORP | 241-NETWORK CONTRACT OFFICE 01 (36C241) | $304,950 | FY2026 |
Cite as: Glassbox VA record view · VA contract (USAspending / FPDS) · CONT_AWD_VA24115J2048_3600_V797P5131B_3600 · retrieved 2026-09-26.